Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 307 clinical trials
Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.

  • 28 Jan, 2021
  • 1 location
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Prospective multicenter phase 2 study using PAD and Thal/Dex combination sequentially.

refractory multiple myeloma
cell transplantation
  • 07 Nov, 2020
  • 1 location
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.

bone scan
metastatic prostate cancer
  • 07 Nov, 2020
  • 1 location
Research for the Molecular Imaging of the HER2 Targeting Tracer

To use the molecular PET radionuclide (Ga-68 or F-18) labelled HER2 Affibody to detect the expression of HER2 in the primary and metastatic lesions in patients with HER2 positive or suspicious positive tumors; to detect the expression heterogeneity of HER2 in the lesions and inter-lesions; to observe the change of …

  • 25 Jan, 2021
  • 1 location
A Phase 2 Single-Center Open Label Study of Autologous Adoptive Cell Therapy Following a Reduced Intensity Non-myeloablative Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

An autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients.

  • 17 Feb, 2021
  • 1 location
A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer

The aim of this study was to evaluate the progression time and efficacy of brain tumors in patients with brain metastases from HER2-positive breast cancer treated with Pyrrolidine and Capecitabine combined with brain radiotherapy.

  • 03 Mar, 2021
  • 1 location
Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients

MAZEPPA is open-label, phase II study to assess the efficacy of a genomic-driven maintenance therapy in terms of PFS in Pancreatic ductal adenocarcinoma (PDAC) patients with disease controlled after 4 months of mFOLFIRINOX chemotherapy as following: Patients with a BRCAness somatic profile: olaparib Arm A. Patients with no BRCAness profile …

  • 27 Jan, 2021
  • 29 locations
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.

bone scan
progesterone receptor
  • 21 Apr, 2021
  • 42 locations
Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer

Magnetic resonance imaging (MRI) has improved detection of clinically significant prostate cancer (PCa). MRI-guided transurethral ultrasound ablation (MRI-TULSA) system incorporates precise diagnosis and simultaneous ablation of prostate tissue enabling lesion-targeted treatment of PCa. Lesion-based treatment strategy spares surrounding healthy tissues from injury, which may improve the outcome of genitourinary function. …

  • 13 May, 2021
  • 1 location
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

The purpose of this study is to find out if treatment with a study drug, durvalumab has beneficial effects in people who have recurrent ovarian clear cell cancer and to determine what effects (both good and bad) it has on them and their cancer.

  • 22 Jan, 2021
  • 2 locations